SkinBioTherapeutics (LSE:SBTX) has appointed Anita Slater as interim Chief Financial Officer for an initial six-month period as the life sciences group looks to strengthen its financial governance and controls. Slater will work alongside the existing interim finance team to support a smooth transition and reinforce the company’s financial framework.
Anita Slater Brings Three Decades of Financial Experience
Slater is a chartered accountant with around 30 years of senior commercial and financial experience spanning start-ups, AIM-listed companies and FTSE top 10 businesses.
Her appointment comes as SkinBioTherapeutics focuses on improving its governance structure while progressing the commercial development of its skin health portfolio. Working with the interim finance team, Slater will help ensure continuity across the group’s financial operations during the leadership transition.
Further Board Appointments Under Discussion
SkinBioTherapeutics is also in advanced discussions regarding the appointment of additional non-executive directors, signalling that further changes to the board could be forthcoming.
The company expects to provide a broader business update by mid-September. The planned update, together with potential new board appointments, should provide shareholders with further information on the group’s strategic priorities and evolving leadership structure.
Profitability and Cash Flow Remain Key Challenges
SkinBioTherapeutics has delivered strong revenue growth, but its overall financial profile continues to be constrained by negative profitability and cash flow.
Technical indicators provide some support, with recent trend and momentum signals showing improvement. However, conventional valuation measures remain difficult to assess positively while the company continues to report losses, resulting in a negative price-to-earnings ratio, while no dividend yield is currently indicated.
More About SkinBioTherapeutics
SkinBioTherapeutics is an AIM-listed UK life sciences company specialising in skin health. Its operations are built around the proprietary SkinBiotix platform, which originated from research conducted at the University of Manchester.
The group follows a dual approach to skin health, developing topical products designed to work externally alongside oral supplements intended to support the skin from within. SkinBioTherapeutics also operates contract manufacturing and distribution activities serving the wider skin and healthcare products market.
Leave a Reply